Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 4 1Phase 3 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

pembrolizumab 1lanreotide 1PM 01183 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT03043664 2023-06-29

PLANET

Duke University

Phase 1/2 Completed
22 enrolled 12 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡